Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients.

@article{Powles2015CharacterisationOL,
  title={Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients.},
  author={Thomas B Powles and Sergio Bracarda and Mei Chen and Elliot Norry and Natalie Compton and Mark Heise and Thomas E. Hutson and Philipp Harter and Christopher L Carpenter and Lini N. Pandite and Neil Kaplowitz},
  journal={European journal of cancer},
  year={2015},
  volume={51 10},
  pages={1293-302}
}
Drug-induced liver chemistry abnormalities, primarily transaminase elevations, are commonly observed in pazopanib-treated patients. This meta-analysis characterises liver chemistry abnormalities associated with pazopanib. Data of pazopanib-treated patients from nine prospective trials were integrated (N=2080). Laboratory datasets were used to characterise the incidence, timing, recovery and patterns of liver events, and subsequent rechallenge with pazopanib. Severe cases of liver chemistry… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
9 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…